choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Rituxan

Rituxan Newsletter
  • The Targeted Pulse: CAR T Label Updates, FDA Approvals, and More 06 Jul 2025 11:27 GMT

    … development this week saw the FDA approve updated labels for chimeric … rituximab (Rituxan) for relapsed follicular lymphoma. This groundbreaking, chemotherapy-free treatment option … for oncologists here. Beyond new drug approvals, this week also highlighted …

  • Oncology Drugs Approved by the FDA in June 02 Jul 2025 14:27 GMT

    … orchiectomy.1 Treatment with darolutamide … multicenter, single-arm trials.3 TRUST-I … Revlimid) and rituximab (Rituxan) for adult patients … ;/www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or …

  • Therapies Which Received FDA Approval in July: What Patients Should Know 01 Jul 2025 18:12 GMT

    … Food and Drug Administration (FDA) approved multiple cancer treatments and combination … oncologist at Weill Cornell Medicine and NewYork-Presbyterian, … with Revlimid (lenalidomide) and Rituxan (rituximab) for adults … two open-label clinical trials, TRUST-I and …

  • OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025 01 Jul 2025 21:03 GMT

    … of Medicine, said in a recent interview. “The drug has … 3, single-arm ENVISION trial (NCT05243550), in which patients … (Revlimid) and rituximab (Rituxan) for adult patients with … TROPION trials and the implications for the NSCLC treatment landscape. …

  • Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL 27 Jun 2025 16:32 GMT

    … (Revlimid) and rituximab (Rituxan) for relapsed/refractory … MD, hematologist/medical oncologist at Rocky Mountain … patients outside of clinical trials. Tafasitamab, a humanized … lymphoma treatment. Poh reflected on the broader implications, stating, …

  • CAR T Transforms Treatment Landscape for Blood Cancers 27 Jun 2025 16:12 GMT

    … participated in the original trials and many that led to … and qualified for a trial we were running at … therapy that combined immunotherapy, [Rituxan], with a small molecule. … attend informational classes, understand the treatment process, and be prepared …

  • Dr Danilov on the Evolution of Chemotherapy-Free Treatment Options in MCL 27 Jun 2025 19:59 GMT

    … Early Clinical Therapeutics, medical director of the … and chronic lymphocytic leukemia treatment paradigms. The emergence … comparator in this trial included rituximab (Rituxan), cyclophosphamide, doxorubicin, … randomized phase 3 trials and smaller phase …

  • Mosunetuxumab/Polatuzmab Vedotin Combo Advances R/R LBCL Treatment Options 27 Jun 2025 00:29 GMT

    … ORR) compared with rituximab (Rituxan), gemcitabine, and oxaliplatin ( … antibody mosunetuzumab and antibody-drug conjugate (ADC) … nonchemotherapeutic option in the treatment landscape. Submissions of … authorities, including the FDA, are anticipated.1 …

  • Novel Targeted, Chemo-Free, and Cellular Therapies Are Poised to Transform Treatment Paradigms in B-Cell Malignancies 25 Jun 2025 14:47 GMT

    … of Early Clinical Therapeutics, medical director of the Early … to R-CHOP [rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, … including] smaller phase 2 [trials] as well as randomized phase … for the treatment of CLL. How has the FDA approval …

  • Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology 24 Jun 2025 21:08 GMT

    … events and few treatment discontinuations. Sunvozertinib … compared with rituximab (Rituxan) plus GemOx (n = … trial (NCT03416530), and 3 phase 2 trials (NCT03295396; NCT02525692; NCT03134131), the drug … 2025, Foresee Pharmaceuticals announced the FDA issued a …

Satisfied with the content?

Continue to create your account.